< Back to search
Filter
1

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

for
Non Small Cell Lung Cancer, Lung Cancer, Breast Cancer,
Location: Boston MA, New Haven CT, New York NY,
Sponsor: SystImmune Inc.

Sex: All

Age: 18+

Code: NCT05983432

Phase1, Recruiting

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

for
Head and Neck Squamous Cell Carcinoma,
Location: Boston MA, Providence RI, New York NY, Charleston SC,
Sponsor: Bicara Therapeutics

Sex: All

Age: 18+

Code: NCT04429542

Phase1, Recruiting

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

for
Advanced Biliary Tract Carcinoma, Advanced Colorectal Carcinoma,
Location: Chicago IL
Sponsor: Northwestern University

Sex: All

Age: 18+

Code: NCT05733000

Phase2, Recruiting

Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...

for
Neurofibroma, Plexiform,
Location: Bethesda MD
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 3 - 35

Code: NCT02390752

Phase1, Recruiting

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

for
Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor,
Location: Boston MA, Baltimore MD, Bethesda MD, Toronto,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 12+

Code: NCT04924075

Phase2, Recruiting

Interested in new solid tumor trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

for
Lung Cancer, Breast Cancer
Location: Hackensack NJ, Montreal, Ottawa, Miami FL, Cleveland OH,
Sponsor: Bristol-Myers Squibb

Sex: All

Age: 18+

Code: NCT06618287

Phase1, Phase2, Recruiting

Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6

for
Cancer
Location: Boston MA
Sponsor: Dana-Farber Cancer Institute

Sex: All

Age: 18+

Code: NCT03310879

Phase2, Recruiting

A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)

for
Neoplasms
Location: Boston MA, New Haven CT, Sherbrooke, New Brunswick NJ,
Sponsor: GlaxoSmithKline

Sex: All

Age: 18+

Code: NCT06551142

Phase1, Recruiting

Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform

for
Early Stage Triple-Negative Breast Carcinoma,
Location: Jacksonville FL, Rochester MN, Phoenix AZ
Sponsor: Mayo Clinic

Sex: All

Age: 18+

Code: NCT06349642

Recruiting

A Study of PSB205 in Subjects With Advanced Solid Tumors

for
Neoplasm Malignant
Location: San Antonio TX
Sponsor: Qilu Puget Sound Biotherapeutics (dba Sound Biologics)

Sex: All

Age: 18+

Code: NCT03986606

Phase1, Recruiting

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

for
Triple Negative Breast Cancer, Breast Cancer,
Location: Boston MA, New York NY, Fairfax VA, Jacksonville FL,
Sponsor: Day One Biopharmaceuticals, Inc.

Sex: All

Age: 18+

Code: NCT05377996

Phase1, Phase2, Recruiting

A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

for
Platinum-resistant Ovarian Cancer, Testicular Cancer,
Location: Boston MA, Providence RI, New York NY, Durham NC,
Sponsor: Context Therapeutics Inc.

Sex: All

Age: 18+

Code: NCT06515613

Phase1, Recruiting

Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors

for
Advanced Cancer
Location: New York NY, Newark DE, Baltimore MD, Bethesda MD,
Sponsor: Riboscience, LLC.

Sex: All

Age: 18+

Code: NCT05270213

Phase1, Recruiting

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

for
Tumor Skin, Metastatic Melanoma, Melanoma, Lung Cancer,
Location: New York NY, Pittsburgh PA, Orlando FL, Louisville KY,
Sponsor: Obsidian Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06060613

Phase1, Phase2, Recruiting

A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors

for
Triple Negative Locally Advanced Non-resectable Breast Cancer,
Location: Boston MA, Toronto, Columbus OH, Nashville TN,
Sponsor: Marengo Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06827613

Phase1, Phase2, Recruiting

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

for
Colorectal Carcinoma, Endometrial Carcinoma, Melanoma,
Location: Boston MA, New York NY, Philadelphia PA,
Sponsor: Children's Oncology Group

Sex: All

Age: 1 - 30

Code: NCT04851119

Phase1, Phase2, Recruiting

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

for
Melanoma, NSCLC, Hepatocellular Carcinoma, Urothelial Cancer,
Location: Pittsburgh PA
Sponsor: Dan Zandberg

Sex: All

Age: 18+

Code: NCT04114136

Phase2, Recruiting

Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC

for
Non-small Cell Lung Cancer(NSCLC),
Location: Fairfax VA
Sponsor: LG Chem

Sex: All

Age: 18+

Code: NCT06332755

Phase1, Recruiting

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

for
Ovarian Cancer, Pancreas Cancer, Urothelial Carcinoma,
Location: New York NY, Rochester NY, Atlanta GA, Denver CO,
Sponsor: Nammi Therapeutics Inc

Sex: All

Age: 18+

Code: NCT06582017

Phase1, Recruiting

GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies

for
Hepatocellular Carcinoma, Hepatocellular Cancer,
Location: Bethesda MD
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18 - 70+

Code: NCT05003895

Phase1, Recruiting